The EORTC Phase IIi trials in prostatic cancer
Robinson, M.R.; Smith, P.H.; Macaluso, M.P.; Sylvester, R.; de Voogt, H.
Progress in Clinical and Biological Research 185a: 243-249
1985
ISSN/ISBN: 0361-7742 PMID: 3898132 Document Number: 264677
Document emailed within 1 workday
Related Documents
Pavone-Macaluso, M.; Lund, F.; Mulder, J.H.; Smith, P.H.; De Pauw, M.; Sylvester, R. 1980: EORTC protocols in prostatic cancer. An interim report Scandinavian Journal of Urology and Nephrology. Supplementum 55: 163-168Suciu, S.; Solbu, G.; Zittoun, R.; Hayat, M.; Willemze, R.; de Witte, T.; Mandelli, F. 1991: Methodology of evaluation in EORTC trials including BMT in acute myelogenous leukemia (AML) in first complete remission (CR). EORTC Leukemia Cooperative Group (LCG) and GIMEMA Bone Marrow Transplantation 7(Suppl 2): 34
Cheson, B.D.; Phillips, P.H.; Trimble, E. 1994: Clinical trials. Referral resource. Phase Ii Ovarian Cancer Trials Oncology 8(4): 73-74
Trimble, E.L.; Schoenfeldt, M. 2004: Clinical trials referral source. Current randomized phase IIi trials in gynecologic cancer Oncology 18(13): 1642; 1645-1646
Zittoun, R.; Mandelli, F.; Willemze, R.; de Witte, T.; Tura, S.; Ferrini, P.R.; Stryckmans, P.; Gattringer, C.; Petti, M.C.; Solbu, G. 1992: Allogeneic versus autologous bone marrow transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase IIi trial (AML8 A). the EORTC Leukemia Cooperative Group and the GIMEMA Group Leukemia 6(Suppl 2): 114-115
Buesa, J.M.; Mouridsen, H.T.; Santoro, A.; Somers, R.; Bramwell, V.; van Oosterom, A.T.; Wagener, T.; Vendrik, C.; Thomas, D. 1984: Treatment of advanced soft tissue sarcomas with low-dose methotrexate: a phase Ii trial by the European Organization of Research on Treatment for Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Cancer Treatment Reports 68(4): 683-684
Jakse, G. 1989: Intravesical instillation of BCG in carcinoma in situ of the urinary bladder. EORTC protocol 30861. EORTC-GU Group Progress in Clinical and Biological Research 310: 187-192
Lee, Y.J.; Wesley, R.A. 1981: Statistical contributions to phase Ii trials in cancer: interpretation, analysis and design Seminars in Oncology 8(4): 403-416
Becouarn, Y.; Rougier, P. 1998: Clinical efficacy of oxaliplatin monotherapy: phase Ii trials in advanced colorectal cancer Seminars in Oncology 25(2 Suppl 5: 23-31
Hou, M-Mo.; Liu, X.; Wheler, J.; Naing, A.; Hong, D.; Bodurka, D.; Schmeler, K.; Tsimberidou, A.; Janku, F.; Zinner, R.; Piha-Paul, S.; Hu, C-Yuan.; Lu, K.; Kurzrock, R.; Fu, S. 2014: Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program Anticancer Research 34(5): 2349-2355
Debruyne, F.M.; Karthaus, H.F.; Schröder, F.H.; de Voogt, H.J.; de Jong, F.H.; Klijn, J.G. 1985: Results of a Dutch Phase Ii trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer Progress in Clinical and Biological Research 185a: 251-270
Yagoda, A. 1977: Future implications of phase 2 chemotherapy trials in ninety-five patients with measurable advanced bladder cancer Cancer Research 37(8 Part 2): 2775-2780
Weissbach, L. 1992: Prospective randomized multicenter phase IIi study of treatment of hormone refractory prostatic cancer: mitomycin C vs. 4-epirubicin vs. estramustine phosphate Der Urologe. Ausg. a 31(1): 62
Hao, X.K. 1993: Radioimmunodetection of prostatic cancer: in vivo 131I-gamma-seminoprotein for diagnosis of prostatic cancer by nuclear imaging Zhonghua Yi Xue Za Zhi 73(11): 655-657; 700
Jaoko, W.G.; Ogutu, H.; Wakasiaka, S.; Malogo, R.; Ndambuki, R.; Nyange, J.; Omosa-Manyonyi, G.; Fast, P.; Schmidt, C.; Verlinde, C.; Smith, C.; Bhatt, K.M.; Ndinya-Achola, J.; Anzala, O. 2009: Pregnancy rates among female participants in phase i and phase IIA AIDS vaccine clinical trials in Kenya East African Medical Journal 86(9): 430-434
Oishi, K.; Arai, Y.; Takeuchi, H.; Yoshida, O. 1993: Side effects of estrogen administration to prostatic cancer patients: clinical and statistical survey of 109 prostatic cancer cases of Kyoto University Hospital Hinyokika Kiyo. Acta Urologica Japonica 39(1): 23-28
Kosmidis, P.A.; Samantas, E.; Fountzilas, G.; Pavlidis, N.; Apostolopoulou, F.; Skarlos, D. 1994: Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase IIi study. Hellenic Cooperative Oncology Group for Lung Cancer Trials Seminars in Oncology 21(3 Suppl 6: 23-30
Jaillon, P.; Dupuis, B. 1989: Prerequisites for phase i and phase Ii clinical trials of drugs Archives des Maladies du Coeur et des Vaisseaux 82(10): 1773-1776
Eisenhauer, E.A.; Evans, W.K.; Raghavan, D.; Desmeules, M.J.; Murray, N.R.; Stuart-Harris, R.; Wilson, K.S. 1986: Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study Cancer Treatment Reports 70(8): 1029-1030
Davis, T.; Schoenfeldt, M. 2004: Clinical trials referral resource. Current phase IIi clinical trials for adults with leukemia or lymphoma Oncology 18(1): 62; 65, 69